Identification

Name
Metoclopramide
Accession Number
DB01233  (APRD00665)
Type
Small Molecule
Groups
Approved, Investigational
Description

A dopamine D2 antagonist that is used as an antiemetic.

Structure
Thumb
Synonyms
  • 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
  • 2-methoxy-5-chloroprocainamide
  • 4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
  • 4-amino-5-chloro-N-(2-(diethylamino)ethyl)-o-anisamide
  • Metoclopramida
  • Metoclopramidum
Product Ingredients
IngredientUNIICASInChI Key
Metoclopramide hydrochloride7B1QZY5SWZ7232-21-5RVFUNJWWXKCWNS-UHFFFAOYSA-N
Metoclopramide hydrochloride monohydrateW1792A2RVD54143-57-6KJBLQGHJOCAOJP-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Maxeran 5mg TabTablet5 mgOralLabs Nordic Laboratories Inc. Subsidary Of M.M.D.C.1984-12-311998-08-12Canada
Maxeran LiqLiquid1 mgOralHoechst Marion Roussel1995-12-312000-07-28Canada
Maxeran-10 (10mg Tablet)Tablet10 mgOralHoechst Marion Roussel1995-12-312000-07-28Canada
Maxeran-5 (5mg Tablet)Tablet5 mgOralHoechst Marion Roussel1996-10-232000-07-28Canada
MetoclopramideInjection, solution10 mg/2mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-08-012017-01-27Us
MetoclopramideInjection, solution5 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines2010-05-01Not applicableUs
MetoclopramideInjection, solution5 mg/mLIntramuscular; IntravenousCardinal Health2010-12-09Not applicableUs
Metoclopramide Hydrochloride InjectionLiquid5 mgIntramuscular; IntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Metoclopramide Hydrochloride Injection HsLiquid5 mgIntravenousBioniche Pharma (Canada) Ltd1999-04-192014-09-11Canada
Metoclopramide OmegaLiquid5 mgIntramuscular; IntravenousOmega Laboratories Ltd2001-04-30Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-metoclop Tab 10mgTablet10 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-metoclop Tab 5mgTablet5 mgOralApotex Corporation1989-12-31Not applicableCanada
MetoclopramideTablet5 mg/1OralProficient Rx LP1990-09-30Not applicableUs
MetoclopramideTablet10 mg/1OralActavis Elizabeth LLC1985-10-172017-07-22Us
MetoclopramideTablet10 mg/1OralBionpharma Inc.2015-12-15Not applicableUs
MetoclopramideTablet10 mg/1OralCardinal Health2013-07-23Not applicableUs
MetoclopramideTablet10 mg/1OralA S Medication Solutions1990-09-30Not applicableUs
MetoclopramideTablet10 mg/1OralAmerincan Health Packaging2013-07-232017-07-31Us
MetoclopramideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-10-17Not applicableUs
MetoclopramideTablet10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1990-09-30Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetoclopramideTablet10 mg/1OralNu Care Pharmaceuticals,inc.1990-09-30Not applicableUs
International/Other Brands
Cerucal / Degan / Elieten / Maxeran / Maxolon / METOZOLV / Plasil1 / Plazilin / Pramin / Primperan / Pulin / Pylomid / Reliveran
Categories
UNII
L4YEB44I46
CAS number
364-62-5
Weight
Average: 299.796
Monoisotopic: 299.14005467
Chemical Formula
C14H22ClN3O2
InChI Key
TTWJBBZEZQICBI-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
IUPAC Name
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
SMILES
CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC

Pharmacology

Indication

For the treatment of gastroesophageal reflux disease (GERD). It is also used in treating nausea and vomiting, and to increase gastric emptying.

Structured Indications
Pharmacodynamics

Metoclopramide, although chemically related to procainamide, does not possess local anesthetic or antiarrhythmic properties. Metoclopramide is used to enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation of the small bowel during radiologic examination. Metoclopramide may be used to treat chemotherapy-induced emesis and as a radiosensitizing agents in the treatment of non-small cell lung carcinoma and glioblastomas in the future.

Mechanism of action

Metoclopramide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in an improved coordination between the body and antrum of the stomach and the upper small intestine. Metoclopramide also decreases reflux into the esophagus by increasing the resting pressure of the lower esophageal sphincter and improves acid clearance from the esophagus by increasing amplitude of esophageal peristaltic contractions. Metoclopramide's dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves. Studies have also shown that high doses of metoclopramide can antagonize 5-hydroxytryptamine (5-HT) receptors in the peripheral nervous system in animals.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
agonist
Human
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 4
agonist
Human
U5-hydroxytryptamine receptor 3A
agonist
Human
UAcetylcholinesterase
inhibitor
Human
Absorption

Rapidly and well absorbed (oral bioavailability 80±15.5%).

Volume of distribution
  • 4.4±0.65 L/kg
Protein binding

30%

Metabolism

Hepatic

Route of elimination

Approximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hours.

Half life

5-6 hr

Clearance
  • 0.67 +/- 0.14 L/hr/kg [infants (0.9-5.4 months) with gastroesophageal reflux (GER)]
Toxicity

Oral, mouse LD50: 280 mg/kg. Signs of overdose include drowsiness, disorientation, and extrapyramidal reactions.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Potassium voltage-gated channel subfamily H member 2---(C;C) / (A;C)A > CEffect Directly StudiedThe presence of this polymorphism in KCNH2 may be associated with increased clinical efficacy with metoclopramide.Details
Alpha-1D adrenergic receptor---(T;T) / (A;T)A > TEffect Directly StudiedThe presence of this polymorphism in ADRA1D may be associated with increased clinical efficacy with metoclopramide.Details
Cytochrome P450 2D6CYP2D6*2A(G;G) / (C;G)C > GADR Directly StudiedPatients with this genotype have reduced metabolism of metoclopramide and may be at a higher risk of experiencing adverse events.Details
Cytochrome P450 2D6CYP2D6*2(A;A) / (A;G)G > AADR Directly StudiedPatients with this genotype have reduced metabolism of metoclopramide and may be at a higher risk of experiencing adverse events.Details
Cytochrome P450 2D6CYP2D6*4(A;A) / (A;G)G > ADirectly Studied EffectPatients with this genotype have reduced metabolism of metoclopramide.Details
Potassium voltage-gated channel subfamily H member 2---(T;T) / (C;T)G > AADR Directly StudiedThe presence of this polymorphism in KCNH2 is associated with higher incidences of adverse events from metoclopramide treatment.Details
Multidrug resistance protein 1---(T;T) / (C;T) / (T;T) / (G;T) / (T;T) / (C;T)T Allele / G > T  … show all Effect Directly StudiedPatients with this polymorphism in ABCB1 may have a reduced response to clomipramine.Details
NADH-cytochrome b5 reductase 3---Not AvailableExon 2 c.129C>A / Exon 2 c.149G>A  … show all ADR InferredRisk of methemglobinemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Metoclopramide.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Metoclopramide.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Metoclopramide.Experimental, Illicit
AbirateroneThe serum concentration of Metoclopramide can be increased when it is combined with Abiraterone.Approved
AcebutololMetoclopramide may increase the bradycardic activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Metoclopramide.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Alaproclate.Experimental
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Metoclopramide.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Metoclopramide.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Metoclopramide.Experimental, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Metoclopramide.Approved, Investigational
AlprenololMetoclopramide may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Metoclopramide.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Metoclopramide.Approved
AmineptineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amineptine.Illicit, Withdrawn
AmiodaroneMetoclopramide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amitriptyline.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amperozide.Experimental
AnagrelideMetoclopramide may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Metoclopramide.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Metoclopramide.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Metoclopramide.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Metoclopramide.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Metoclopramide.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Arecoline.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.Approved, Investigational
ArotinololMetoclopramide may increase the bradycardic activities of Arotinolol.Approved, Investigational
Arsenic trioxideMetoclopramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMetoclopramide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Metoclopramide.Investigational
AtenololMetoclopramide may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe metabolism of Metoclopramide can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Metoclopramide.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Metoclopramide.Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Metoclopramide.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Azaperone.Investigational, Vet Approved
AzithromycinMetoclopramide may increase the QTc-prolonging activities of Azithromycin.Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Metoclopramide.Approved, Investigational
BedaquilineMetoclopramide may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololMetoclopramide may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Metoclopramide.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Benperidol.Investigational
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Metoclopramide.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Metoclopramide.Approved, Vet Approved
BetaxololThe metabolism of Metoclopramide can be decreased when combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Bethanechol.Approved
BevantololMetoclopramide may increase the bradycardic activities of Bevantolol.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Bifeprunox.Investigational
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Metoclopramide.Approved, Investigational
BisoprololMetoclopramide may increase the bradycardic activities of Bisoprolol.Approved
BopindololMetoclopramide may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Metoclopramide.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metoclopramide.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Bromperidol.Investigational
BucindololMetoclopramide may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Metoclopramide.Approved
BufuralolMetoclopramide may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololMetoclopramide may increase the bradycardic activities of Bupranolol.Approved
BupropionThe metabolism of Metoclopramide can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metoclopramide.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Butaperazine.Experimental
ButylscopolamineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Metoclopramide.Approved, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Metoclopramide.Approved
CarbacholThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Carbachol.Approved
CariprazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cariprazine.Approved
CarteololMetoclopramide may increase the bradycardic activities of Carteolol.Approved
CarvedilolMetoclopramide may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Metoclopramide can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololMetoclopramide may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibMetoclopramide may increase the QTc-prolonging activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cevimeline.Approved
ChloroquineMetoclopramide may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Metoclopramide.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholecalciferolThe metabolism of Metoclopramide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Metoclopramide.Approved, Investigational
CimetidineThe metabolism of Metoclopramide can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Metoclopramide can be decreased when combined with Cinacalcet.Approved
CiprofloxacinMetoclopramide may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMetoclopramide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.Approved
ClarithromycinMetoclopramide may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Metoclopramide can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Metoclopramide can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Metoclopramide.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Metoclopramide.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Metoclopramide.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Metoclopramide.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clomipramine.Approved, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clopenthixol.Experimental
CloranololMetoclopramide may increase the bradycardic activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Metoclopramide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.Approved
CobicistatThe serum concentration of Metoclopramide can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Metoclopramide can be decreased when combined with Cocaine.Approved, Illicit
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Metoclopramide.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Metoclopramide.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Metoclopramide.Approved
CrizotinibMetoclopramide may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyclobenzaprine.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Metoclopramide.Approved
CyclosporineMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational, Vet Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Metoclopramide.Approved, Investigational
DarifenacinThe metabolism of Metoclopramide can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Metoclopramide can be increased when it is combined with Darunavir.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Metoclopramide.Approved
DelavirdineThe metabolism of Metoclopramide can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desipramine.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Metoclopramide.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Metoclopramide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Metoclopramide.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Metoclopramide.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Metoclopramide.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Metoclopramide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Metoclopramide.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Metoclopramide.Withdrawn
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Metoclopramide.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dibenzepin.Experimental
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Metoclopramide.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Metoclopramide.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Metoclopramide.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Metoclopramide.Approved
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metoclopramide.Approved
DiphenhydramineThe metabolism of Metoclopramide can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Dipyridamole.Approved
DisopyramideMetoclopramide may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dixyrazine.Experimental
DofetilideMetoclopramide may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMetoclopramide may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMetoclopramide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Doxepin.Approved
DronedaroneMetoclopramide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Metoclopramide.Approved, Vet Approved
DuloxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ecopipam.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Metoclopramide.Approved, Investigational
EliglustatMetoclopramide may increase the QTc-prolonging activities of Eliglustat.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Metoclopramide.Experimental
EpanololMetoclopramide may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Metoclopramide.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Metoclopramide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metoclopramide.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Metoclopramide.Approved
ErythromycinMetoclopramide may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Esmirtazapine.Investigational
EsmololMetoclopramide may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Metoclopramide.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Metoclopramide.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Metoclopramide.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Metoclopramide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Etoperidone.Withdrawn
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Metoclopramide.Experimental
FencamfamineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metoclopramide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoclopramide.Approved
FlecainideMetoclopramide may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluanisoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluanisone.Experimental
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Metoclopramide.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Metoclopramide.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Metoclopramide.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Metoclopramide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Metoclopramide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Metoclopramide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Metoclopramide.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Metoclopramide.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Metoclopramide.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Metoclopramide.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Metoclopramide.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Metoclopramide.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Metoclopramide.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Metoclopramide.Approved, Investigational, Withdrawn
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Metoclopramide.Approved, Investigational
Gadobenic acidMetoclopramide may increase the QTc-prolonging activities of Gadobenic acid.Approved
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Metoclopramide.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Metoclopramide.Approved
GemifloxacinMetoclopramide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Metoclopramide.Approved, Investigational, Vet Approved
GoserelinMetoclopramide may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMetoclopramide may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Metoclopramide is combined with GTS-21.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Metoclopramide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Metoclopramide.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Metoclopramide.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Metoclopramide.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Metoclopramide.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Metoclopramide.Approved
IbutilideMetoclopramide may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Indalpine.Investigational, Withdrawn
IndenololMetoclopramide may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Metoclopramide can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Metoclopramide.Approved
IprindoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iprindole.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.Approved
IsoniazidThe metabolism of Metoclopramide can be decreased when combined with Isoniazid.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Metoclopramide.Investigational
KetoconazoleThe metabolism of Metoclopramide can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolMetoclopramide may increase the bradycardic activities of Labetalol.Approved
LandiololMetoclopramide may increase the bradycardic activities of Landiolol.Investigational
LenvatinibMetoclopramide may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideMetoclopramide may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololMetoclopramide may increase the bradycardic activities of Levobunolol.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Metoclopramide.Approved
LevofloxacinMetoclopramide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Metoclopramide.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Metoclopramide.Approved
LobelineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lobeline.Investigational
LofepramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lofepramine.Experimental
LopinavirMetoclopramide may increase the QTc-prolonging activities of Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Metoclopramide.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Metoclopramide.Approved
LoxapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.Approved
LumefantrineMetoclopramide may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.Approved
ManidipineThe metabolism of Metoclopramide can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Metoclopramide.Approved
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Metoclopramide.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Metoclopramide.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Metoclopramide.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Metoclopramide.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Metoclopramide.Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Melperone.Approved, Investigational
MepindololMetoclopramide may increase the bradycardic activities of Mepindolol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.Approved, Investigational
MethacholineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methacholine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metoclopramide.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Metoclopramide.Approved, Investigational
MethotrimeprazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Metoclopramide.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Metoclopramide.Approved
MetipranololMetoclopramide may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Metoclopramide.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Metoclopramide.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide.Approved
MidostaurinThe metabolism of Metoclopramide can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Metoclopramide.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Milnacipran.Approved
MirabegronThe metabolism of Metoclopramide can be decreased when combined with Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mirtazapine.Approved
MivacuriumMetoclopramide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Metoclopramide.Approved, Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mosapramine.Experimental
MoxifloxacinMetoclopramide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NadololMetoclopramide may increase the bradycardic activities of Nadolol.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Metoclopramide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Metoclopramide.Investigational
NebivololMetoclopramide may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Metoclopramide can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Metoclopramide can be decreased when combined with Nicardipine.Approved
NicotineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nicotine.Approved
NilotinibMetoclopramide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metoclopramide.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nortriptyline.Approved
OfloxacinMetoclopramide may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Metoclopramide.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Opipramol.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Metoclopramide.Approved
OsanetantThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant.Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Metoclopramide.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Metoclopramide.Investigational
OxprenololMetoclopramide may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Metoclopramide.Approved, Investigational
OxypertineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Oxypertine.Experimental
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Metoclopramide.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Metoclopramide.Approved
PanobinostatThe serum concentration of Metoclopramide can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Metoclopramide.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.Approved, Investigational
PazopanibMetoclopramide may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Metoclopramide can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololMetoclopramide may increase the bradycardic activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Penfluridol.Experimental
PentamidineMetoclopramide may increase the QTc-prolonging activities of Pentamidine.Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Metoclopramide.Approved
PerazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perazine.Investigational
PerflutrenMetoclopramide may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metoclopramide.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Metoclopramide.Experimental
PilocarpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pilocarpine.Approved
PimozideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.Approved
PindololMetoclopramide may increase the bradycardic activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipamperone.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Metoclopramide.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipotiazine.Approved, Investigational
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Metoclopramide.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Metoclopramide.Investigational
Platelet Activating FactorMetoclopramide may increase the bradycardic activities of Platelet Activating Factor.Experimental
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.Approved, Investigational, Vet Approved
PractololMetoclopramide may increase the bradycardic activities of Practolol.Approved
PramipexoleThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Metoclopramide.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Metoclopramide.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Metoclopramide.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Metoclopramide.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Metoclopramide.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Metoclopramide.Experimental, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prilocaine.Approved
PrimaquineMetoclopramide may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideMetoclopramide may increase the QTc-prolonging activities of Procainamide.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Metoclopramide.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Metoclopramide.Approved
PromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promethazine.Approved
PropafenoneMetoclopramide may increase the QTc-prolonging activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Metoclopramide.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Propericiazine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Metoclopramide.Approved, Investigational
PropranololMetoclopramide may increase the bradycardic activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Protriptyline.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide.Approved
QuinidineMetoclopramide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMetoclopramide may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Raclopride.Investigational
RanolazineThe metabolism of Metoclopramide can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumMetoclopramide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Metoclopramide.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ritanserin.Investigational
RitonavirThe metabolism of Metoclopramide can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Metoclopramide.Approved
RolapitantThe metabolism of Metoclopramide can be decreased when combined with Rolapitant.Approved
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.Approved, Investigational
RotigotineThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Metoclopramide.Approved
SaquinavirMetoclopramide may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Metoclopramide.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Metoclopramide.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertraline.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sodium Nitrite.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Metoclopramide.Approved
SotalolMetoclopramide may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolThe metabolism of Metoclopramide can be decreased when combined with Stiripentol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Metoclopramide.Approved
SulfisoxazoleMetoclopramide may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Metoclopramide.Approved, Investigational
TalinololMetoclopramide may increase the bradycardic activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metoclopramide.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Metoclopramide.Approved
TelavancinMetoclopramide may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMetoclopramide may increase the QTc-prolonging activities of Telithromycin.Approved
TerbinafineThe metabolism of Metoclopramide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololMetoclopramide may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrahydropalmatine.Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Metoclopramide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Metoclopramide can be decreased when combined with Ticlopidine.Approved
TimololMetoclopramide may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Metoclopramide.Approved
TipranavirThe metabolism of Metoclopramide can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Metoclopramide.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Metoclopramide.Approved, Investigational
ToremifeneMetoclopramide may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metoclopramide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Metoclopramide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Metoclopramide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Metoclopramide.Approved
TrimetazidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimetazidine.Approved, Investigational
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Metoclopramide.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimipramine.Approved
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Metoclopramide.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Metoclopramide.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Metoclopramide.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Metoclopramide.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Metoclopramide.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Metoclopramide.Approved
VandetanibMetoclopramide may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Metoclopramide.Approved
VemurafenibMetoclopramide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Veralipride.Experimental
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Metoclopramide.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metoclopramide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Metoclopramide.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Food reduces availability, take 30 minutes before meals. Avoid alcohol.

References

Synthesis Reference
US3177252
General References
  1. JUSTIN-BESANCON L, LAVILLE C: [ANTIEMETIC ACTION OF METOCLOPRAMIDE WITH RESPECT TO APOMORPHINE AND HYDERGINE]. C R Seances Soc Biol Fil. 1964;158:723-7. [PubMed:14186927]
  2. Tonini M, Candura SM, Messori E, Rizzi CA: Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res. 1995 May;31(5):257-60. [PubMed:7479521]
External Links
Human Metabolome Database
HMDB15363
KEGG Drug
D00726
KEGG Compound
C07868
PubChem Compound
4168
PubChem Substance
46505631
ChemSpider
4024
BindingDB
48320
ChEBI
107736
ChEMBL
CHEMBL86
Therapeutic Targets Database
DAP000530
PharmGKB
PA450475
IUPHAR
241
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Metoclopramide
ATC Codes
A03FA01 — Metoclopramide
AHFS Codes
  • 56:32.00 — Prokinetic Agents
FDA label
Download (90.1 KB)
MSDS
Download (73.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentPost-Traumatic Headaches1
1CompletedDiagnosticHemorrhage, Gastrointestinal1
1TerminatedBasic ScienceDrug Metabolism, Poor, CYP2D6-RELATED1
1, 2CompletedTreatmentEnteral Feeding Intolerance (EFI)1
2CompletedTreatmentDelayed Gastric Emptying / Diabetes Mellitus (DM) / Diabetic Gastroparesis / Gastroparesis1
2CompletedTreatmentInfant, Newborn, Diseases1
2CompletedTreatmentMigraine Disorders1
2CompletedTreatmentMigrainous Headache1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2Not Yet RecruitingTreatmentNuclear radiation emergency / Nutrition, Enteral1
2RecruitingTreatmentEnteral Feeding Intolerance (EFI)1
2TerminatedSupportive CareVomiting1
2TerminatedTreatmentBenign Headache1
2TerminatedTreatmentGastroparesis1
2WithdrawnTreatmentMyelodysplastic Syndromes1
2, 3WithdrawnTreatmentHeadaches1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentBreastfeeding1
3CompletedTreatmentClozapine-induced Hypersalivation1
3CompletedTreatmentElective Caesarean Section Surgeries1
3CompletedTreatmentMigraines1
3Enrolling by InvitationTreatmentAutonomic Nervous System Diseases / Dopamine Beta-Hydroxylase Deficiency / Idiopathic orthostatic hypotension / Orthostatic Intolerance1
3Not Yet RecruitingTreatmentAcute Gastroenteritis / Vomiting1
3RecruitingPreventionChemotherapy Induced Vomiting / Leukemia Acute Myeloid Leukemia (AML)1
3RecruitingTreatmentGastroschisis1
3RecruitingTreatmentHeadaches / Intranasal Ketamine1
3RecruitingTreatmentHyperemesis Gravidarum1
3RecruitingTreatmentNausea / Vomiting1
3RecruitingTreatmentPost-Traumatic Headaches1
3RecruitingTreatmentTumors, Solid1
3TerminatedPreventionSepsis1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentVomiting1
3Unknown StatusDiagnosticHemorrhage, Gastrointestinal / Refractory Anemia / Small Bowel Diseases1
3Unknown StatusPreventionNausea / Vomiting1
3WithdrawnTreatmentMigraines1
4CompletedNot AvailablePill Capsule Endoscopy Completion Rates1
4CompletedPreventionInfants, Premature1
4CompletedPreventionNausea / Satisfaction / Vomiting1
4CompletedPreventionPregnancy1
4CompletedPreventionProlonged First Stage of Labor1
4CompletedTreatmentHeadaches1
4CompletedTreatmentMigraine Disorders1
4CompletedTreatmentMigraine With Aura / Migraine Without Aura / Probable Migraine1
4CompletedTreatmentMigraines2
4CompletedTreatmentMigrainous Headache1
4CompletedTreatmentMigrainous Headache / Nausea / Restlessness1
4CompletedTreatmentNausea / Vertigo / Vomiting1
4CompletedTreatmentNausea / Vomiting1
4CompletedTreatmentExtra-pyramidal symptoms / Nausea1
4CompletedTreatmentOpioid Induced Pharyngeal and Esophageal Dysfunction1
4CompletedTreatmentPostoperative Function Level / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4Not Yet RecruitingTreatmentCancers / Nausea / Vomiting1
4Not Yet RecruitingTreatmentMigraines1
4Not Yet RecruitingTreatmentReflux, Gastroesophageal1
4RecruitingPreventionMigraines1
4RecruitingTreatmentAcute Myocardial Infarction (AMI)1
4RecruitingTreatmentMigraines1
4RecruitingTreatmentOpiate withdrawal symptoms1
4RecruitingTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4SuspendedTreatmentMigrainous Headache1
4Unknown StatusTreatmentMigraine, Acute1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedDiagnosticColorectal Cancer Screening1
Not AvailableCompletedDiagnosticGastric Transit Time1
Not AvailableCompletedPreventionAkathisia / Nausea1
Not AvailableCompletedPreventionCesarean Delivery1
Not AvailableCompletedPreventionHeadaches1
Not AvailableCompletedTreatmentBreastfeeding1
Not AvailableCompletedTreatmentCancers1
Not AvailableEnrolling by InvitationTreatmentMigrainous Headache1
Not AvailableNot Yet RecruitingTreatmentAssisted Reproductive Technology therapy / Poor Responder1
Not AvailableRecruitingBasic ScienceHealth1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingTreatmentHigh Altitude Headache / Other and unspecified effects of high altitude1
Not AvailableTerminatedTreatmentFeeding Disorder / Infants, Premature / Nutrition Disorder1
Not AvailableTerminatedTreatmentNausea1
Not AvailableTerminatedTreatmentPrimary Headaches (Includes Migraines, Tension, Cluster Headaches)1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentPost Concussive Headache / Post Concussive Syndrome1
Not AvailableWithdrawnTreatmentPost Operative Nausea and Vomiting (PONV) / Rescue Emetic Therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidOral1 mg
InjectionIntramuscular; Intravenous5 mg/mL
Injection, solutionIntramuscular; Intravenous10 mg/2mL
Injection, solutionIntramuscular; Intravenous5 mg/mL
SolutionOral10 mg/10mL
SolutionOral5 mg/5mL
TabletOral10 mg/1
TabletOral5 mg/1
InjectionIntravenous5 mg/mL
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral5 mg/1
LiquidIntramuscular; Intravenous5 mg
LiquidIntravenous5 mg
SolutionOral5 mg
TabletOral10 mg
TabletOral5 mg
SyrupOral1 mg
Prices
Unit descriptionCostUnit
Metoclopramide hcl powder7.65USD g
Reglan 10 mg tablet1.81USD tablet
Reglan 5 mg tablet1.41USD tablet
Metoclopramide Hydrochloride 5 mg/ml1.39USD ml
Reglan 5 mg/ml vial0.56USD ml
Metoclopramide HCl 5 mg tablet0.43USD tablet
Metoclopramide 5 mg tablet0.33USD tablet
Metoclopramide 10 mg tablet0.28USD tablet
Metoclopramide 5 mg/ml ampul0.28USD ml
Metoclopramide HCl 10 mg tablet0.27USD tablet
Metoclopramide HCl 5 mg/5ml Solution0.06USD ml
Apo-Metoclop 10 mg Tablet0.06USD tablet
Apo-Metoclop 5 mg Tablet0.06USD tablet
Nu-Metoclopramide 10 mg Tablet0.06USD tablet
Nu-Metoclopramide 5 mg Tablet0.06USD tablet
Pms-Metoclopramide 10 mg Tablet0.06USD tablet
Pms-Metoclopramide 5 mg Tablet0.06USD tablet
Pms-Metoclopramide 1 mg/ml Liquid0.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us
US6413549No1997-07-112017-07-11Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)147.25 °CPhysProp
water solubility200 mg/L (at 25 °C)MERCK (1989)
logP2.62HANSCH,C ET AL. (1995)
logS-3.18ADME Research, USCD
pKa9.27 (at 25 °C)EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.31 mg/mLALOGPS
logP2.18ALOGPS
logP1.4ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)14.49ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity83.52 m3·mol-1ChemAxon
Polarizability32.7 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.979
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7687
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8783
Renal organic cation transporterNon-inhibitor0.7276
CYP450 2C9 substrateNon-substrate0.8602
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6375
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9099
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6223
Ames testNon AMES toxic0.5378
CarcinogenicityNon-carcinogens0.6142
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6332 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Inhibitor0.8579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-10fdf9db1550886fc034
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-fcc278321866ecdee26f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0193000000-c044c04d9d51d66ba5a9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0290000000-45d3c52d766c4cd8ae93
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-003r-0970000000-2f2d709cad2c27f798e5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0920000000-ccce0f42f04edf0ecfb3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0900000000-93aec7dddb8a098f7483
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-e7b25ddf867c24be5347
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0093000000-dc0ce524de60c6a189a7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0290000000-2bca02d9f4cee5acca4e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-003r-0970000000-50fe530dffb9aa59d433
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-001i-0920000000-0bb9973fdbe0820dc3d1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00lr-0900000000-4cc6fae9bec9d4c40dbb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0090000000-1c4a27b221c7a053d2c3
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fb9-0595000000-db3b50f051cfcc835a69

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminophenyl ethers. These are aromatic compounds that contain a phenol ether, which carries an amine group on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Aminophenyl ethers
Direct Parent
Aminophenyl ethers
Alternative Parents
Methoxyanilines / Phenoxy compounds / Methoxybenzenes / Anisoles / Chlorobenzenes / Alkyl aryl ethers / Aryl chlorides / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids
show 4 more
Substituents
Aminophenyl ether / Methoxyaniline / Phenoxy compound / Anisole / Methoxybenzene / Aniline or substituted anilines / Alkyl aryl ether / Chlorobenzene / Halobenzene / Aryl chloride
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, substituted aniline, benzamides, monochlorobenzenes (CHEBI:107736)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Burger DM, Wiestner T, Hubler M, Binder H, Keiser M, Arnold S: Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers. J Vet Med A Physiol Pathol Clin Med. 2006 Mar;53(2):97-107. [PubMed:16466463]
  4. Hammer D: Gastroesophageal reflux and prokinetic agents. Neonatal Netw. 2005 Mar-Apr;24(2):51-8; quiz 59-62. [PubMed:15835479]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. See RE, Lynch AM, Sorg BA: Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats. Neuroscience. 1996 May;72(1):99-104. [PubMed:8730709]
  3. Harrold MW, Sriburi A, Matsumoto K, Miller DD, Farooqui T, Uretsky N: The interaction of ammonium, sulfonium, and sulfide analogues of metoclopramide with the dopamine D2 receptor. J Med Chem. 1993 Oct 15;36(21):3166-70. [PubMed:8230103]
  4. Kishibayashi N, Karasawa A: Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats. Jpn J Pharmacol. 1995 Jan;67(1):45-50. [PubMed:7745844]
  5. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R: Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol Res. 1996 Jul-Aug;34(1-2):65-72. [PubMed:8981558]
  6. Dahlof CG, Hargreaves RJ: Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia. 1998 Nov;18(9):593-604. [PubMed:9876882]
  7. Hammer D: Gastroesophageal reflux and prokinetic agents. Neonatal Netw. 2005 Mar-Apr;24(2):51-8; quiz 59-62. [PubMed:15835479]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR4
Uniprot ID
Q13639
Uniprot Name
5-hydroxytryptamine receptor 4
Molecular Weight
43760.975 Da
References
  1. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H: Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009 Mar;16(1):281-90. doi: 10.1677/ERC-08-0190. Epub 2008 Oct 23. [PubMed:18948374]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Costall B, Gunning SJ, Naylor RJ, Tyers MB: The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol. 1987 Jun;91(2):263-4. [PubMed:2955843]
Details
5. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Petroianu G, Arafat K, Kosanovic M, Saleh A, Camasamudram V, Hasan MY: In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). J Appl Toxicol. 2003 Nov-Dec;23(6):447-51. [PubMed:14635269]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 11, 2017 13:04